Synonyms: Betmiga® | Myrbetriq® | YM-178
mirabegron is an approved drug (FDA and EMA (2012))
Compound class:
Synthetic organic
Comment: Mirabegron is a β3-adrenoceptor agonist muscle relaxant. It has been reported to exert effects on cellular metabolism in adipocytes. This latter action is β3-adrenoceptor-dependent, and improves glucose handling in vivo [5].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖![]() View more information in the IUPHAR Pharmacology Education Project: mirabegron |
|
References |
1. Badawi JK, Seja T, Uecelehan H, Honeck P, Kwon ST, Bross S, Langbein S. (2007)
Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology, 69 (4): 785-90. [PMID:17445682] |
2. Brucker BM, King J, Mudd Jr PN, McHale K. (2022)
Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors. Curr Ther Res Clin Exp, 96: 100674. [PMID:35693456] |
3. Dehvari N, da Silva Junior ED, Bengtsson T, Hutchinson DS. (2018)
Mirabegron: potential off target effects and uses beyond the bladder. Br J Pharmacol, 175 (21): 4072-4082. [PMID:29243229] |
4. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020)
The metabolic effects of mirabegron are mediated primarily by β3 -adrenoceptors. Pharmacol Res Perspect, 8 (5): e00643. [PMID:32813332] |
5. Dehvari N, Sato M, Bokhari MH, Kalinovich A, Ham S, Gao J, Nguyen HTM, Whiting L, Mukaida S, Merlin J et al.. (2020)
The metabolic effects of mirabegron are mediated primarily by β3‐adrenoceptors. Pharmacology Research & Perspectives, 8 (5): e00643. DOI: 10.1002/prp2.643 |
6. Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, Sasamata M. (2013)
In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats. Naunyn Schmiedebergs Arch Pharmacol, 386 (3): 247-53. [PMID:23239087] |
7. Nomiya M, Yamaguchi O. (2003)
A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol, 170 (2 Pt 1): 649-53. [PMID:12853849] |
8. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. (2007)
Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther, 321 (2): 642-7. [PMID:17293563] |
9. Yamaguchi O. (2002)
Beta3-adrenoceptors in human detrusor muscle. Urology, 59 (5 Suppl 1): 25-9. [PMID:12007519] |